Relationship between expression of PD-L1 and microsatellite instability of colorectal cancer and its significance
-
摘要:
目的 研究PD-L1在结直肠癌(colorectal cancer, CRC)中的表达及临床意义. 方法 选取2015年1月至2016年1月在郑州大学附属肿瘤医院接受CRC根治性手术的患者210例，分为微卫星高度不稳定（high-frequency microsatellite instability，MSI-H）、微卫星低度不稳定（low-frequency microsatellite instability，MSI-L）、微卫星稳定（microsatellite stable，MSS）3个组，采用免疫组织化学法检测各组织标本中细胞程序性死亡配体1（Programmed cell death 1 ligand 1，PD-L1）的表达，分析PD-L1在各型CRC中的表达特点。 结果 PD-L1在低分化CRC中的表达高于中、高分化CRC（P＜0.05），PD-L1在MSI-H的CRC中阳性率为75.8%，在MSIL/MSS中的阳性率为9.3%，两组比较差异具有统计学意义（P＜0.05）。 结论 PD-L1在部分CRC癌组织中阳性表达，尤其是在MSIH的CRC阳性率显著高于MSI-L及MSS的CRC。PD-L1阻断剂对MSI-H的CRC患者疗效可能更好。 Abstract:Objective To investigate the expression and clinical significance of PD-L1 in colorectal cancer(CRC). Methods A total of210 CRC patients who accepted radical surgery in our hospital from January 2015 to January 2016 were divided into three groups, namely, high-frequency microsatellite instability(MSI-H), low-frequency microsatellite instability(MSI-L), and microsatellite stable(MSS).The expression of PD-L1 was detected by immunohistochemistry, and the expression characteristics of PD-L1 in different typesof CRC were analyzed. Results CRC cases with low differentiation had a higher expression of PD-L1 than CRC patients with high differentiation(P < 0.05).PD-L1 had a positive rate of 75.8% in the MSI-H group and a rate of 9.3% in the MSI-L and MSS groups, wherein thedifference between the two groups was statistically significant(P < 0.05). Conclusion D-L1 was positively expressed in some CRC tumor tissues, and its positive rate was significantly higher in MSI-H than in MSI-L and MSS.The therapeutic effect of a PD-L1 blocker forpatients with MSI-H CRC might be preferable. -
Key words:
- PD-L1 /
- colorectal cancer /
- immunohistochemistry /
- significance
-
图 1 PD-L1在CRC癌组织与癌旁正常组织中的表达
Figure 1. Expression of PD-L1 in cancer and paracancer tissues of CRC
A. Normal colon tissue (H&E staining); B. Normal colon tissue (PD-L1 staining); C. Cancer tissue (H&E staining); D. cancer tissue (PD-L1 staining, ×200)
表 1 MSI引物及特征
Table 1. MST primers and characteristics
表 2 CRC的MSI检测结果
Table 2. Detection of MSI in CRC
表 3 PD-L1在CRC中肿瘤组织与癌旁组织中的表达
Table 3. Expression of PD-L1 in cancer and paracancer tissues of CRC
表 4 PD-L1与CRC的临床病理特征关系
Table 4. Relationship of PD-L1 with clincopathological characteristics of CRC
表 5 PD-L1在MSI-CRC中的表达
Table 5. Expression of PD-L1 in MSI-CRC
-
[1] 沈胤晨, 石远凯, 韩晓红.结直肠癌靶向治疗研究进展[J].中华病理学杂志, 2015, 44(6):430-433. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZLSW201505001009.htmShen YC, Shi YK, Han XH.Advances in targeted therapy of colorectal cancer[J].Chin J Patho, 2015, 44(6):430-433. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZLSW201505001009.htm [2] 中华医学会消化内镜学分会, 中国抗癌协会肿瘤内镜学专业委员会.中国早期结直肠癌筛查及内镜诊治指南(2014, 北京)[J].中华医学杂志, 2015, 95(28):2235-2252. doi: 10.3760/cma.j.issn.0376-2491.2015.28.002Chinese Medical Association digestive endoscopy credits, China Anti-Cancer Association of Cancer Endoscopy professional committee.China early colorectal cancer screening and endoscopic diagnosis and treatment guidelines(2014, Beijing)[J].Chin J Med, 2015, 95(28):2235-2252. doi: 10.3760/cma.j.issn.0376-2491.2015.28.002 [3] Tao L, Rui M, Jiye Z, et al.Blockade of the OX40/OX40L pathwayand induction of PD-L1 synergistically protects mouse islet allografts from rejection[J].Chin Med J(Engl), 2014, 127(14):2686-2692. https://www.researchgate.net/publication/264092694_Blockade_of_the_OX40OX40L_pathway_and_induction_of_PD-L1_synergistically_protects_mouse_islet_allografts_from_rejection [4] 张楠, 曾园园, 黄建安.免疫卡控点分子PD-1/PD-L1在非小细胞肺癌治疗中的研究进展[J].中华医学杂志, 2016, 96(24):1951-1953. doi: 10.3760/cma.j.issn.0376-2491.2016.24.020Zhang N, Zeng YY, Huang JA.Advances in the study of PD-1/PD-L1in the treatment of non-small cell lung cancer[J].Chin J Med, 2016, 96(24):1951-1953. doi: 10.3760/cma.j.issn.0376-2491.2016.24.020 [5] 王丽, 吴昌平, 蒋敬庭.协同刺激分子PD-L1、B7-H3与B7-H4在卵巢癌中的表达及其意义[J].临床肿瘤学杂志, 2013, 18(7):663-667. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201307022.htmWang L, Wu CP, Jiang JT.Expression of co-stimulatory molecules PD-L1, B7-H3 and B7-H4 in ovarian cancer and its significance[J].J Clin Oncol, 2013, 18(7):663-667. http://www.cnki.com.cn/Article/CJFDTOTAL-LCZL201307022.htm [6] 叶因涛, 王晨, 孙蓓.PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展[J].中国肿瘤临床, 2015, 42(24):1178-1182. doi: 10.3969/j.issn.1000-8179.2015.24.803Ye YT, Wang C, Sun B.Advances in the study of PD-1/PD-L1 inhibitors in tumor immunotherapy[J].Chin J Clin Oncol, 2015, (24):1178-1182. doi: 10.3969/j.issn.1000-8179.2015.24.803 [7] 姚宏伟, 刘荫华.第7版结直肠癌TNM分期(2010) 更新内容解读[J].中华外科杂志, 2010, 48(21):1601-1604. doi: 10.3760/cma.j.issn.0529-5815.2010.21.001Yao HW, Liu YH.The seventh edition of colorectal cancer TNM staging(2010) updated content interpretation[J].Chin J Surg, 2010, 48(21):1601-1604. doi: 10.3760/cma.j.issn.0529-5815.2010.21.001 [8] 杨军, 康安静, 苏宝山, 等.免疫组织化学检测结果判读进展[J].中华临床医师杂志, 2014, 27(8)3699-3703. http://www.cnki.com.cn/Article/CJFDTOTAL-ZLYD201420025.htmYang J, Kang AJ, Su BS, et al.Advances in Immunohistochemical Detection[J].Chin J Clinicians, 2014, 27(8):3699-3703. http://www.cnki.com.cn/Article/CJFDTOTAL-ZLYD201420025.htm [9] 张澍田.中国早期结直肠癌及癌前病变筛查与诊治[J].中华医学信息导报, 2016, 31(17):14. doi: 10.3760/cma.j.issn.1000-8039.2016.17.011Zhang PT.Screening, diagnosis and treatment of early colorectalcancer and precancerous lesion in China[J].Chin J Med Inform, 2016, 31(17):14. doi: 10.3760/cma.j.issn.1000-8039.2016.17.011 [10] 禹汇川, 骆衍新, 王小琳, 等.直肠癌根治术后的复发类型对复发后远期生存的影响[J].中华医学杂志, 2016, 96(8):625-628. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201318055.htmYu HC, Luo YX, Wang XL, et al.Effects of recurrence types on postoperative long -term survival after rectal cancer[J].Chin J Med, 2016, 96(8):625-628. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201318055.htm [11] 皮艳娜, 肖毅, 王智凤, 等.新辅助放化疗对中低位直肠癌患者肛门直肠功能的影响[J].中华医学杂志, 2014, 94(24):1857-1860. doi: 10.3760/cma.j.issn.0376-2491.2014.24.004Pi YN, Xiao Y, Wang ZF, et al.Effect of neoadjuvant chemotherapyand chemotherapy on anorectal function in patients with low rectal cancer[J].Chin J Med, 2014, 94(24):1857-1860. doi: 10.3760/cma.j.issn.0376-2491.2014.24.004 [12] Seledtsova GV, Shishkov AA, Kaschenko EA, et al.Xenogeneic cellbased vaccine therapy for colorectal cancer: Safety, association ofclinical effects with vaccine-induced immune responses[J].BiomedPharmacother, 2016, 83:1247-1252. [13] Halama N, Zoernig I, Berthel A, et al.Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively byAnti-CCR5 therapy in cancer patients[J].Cancer Cell, 2016, 29(4):587-601. doi: 10.1016/j.ccell.2016.03.005 [14] Droeser RA, Hirt C, Viehl CT, et al.Clinical impact of programmedcell death ligand 1 expression in colorectal cancer[J].Eur J Cancer, 2013, 49(9):2233-2242. doi: 10.1016/j.ejca.2013.02.015 [15] Llosa NJ, Cruise M, Tam A, et al.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints[J].Cancer Discov, 2015, 5(1):43-51. doi: 10.1158/2159-8290.CD-14-0863 [16] Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, et al.PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumorinfiltrating lymphocytes[J].Mod Pathol, 2016, 29(9):1104-1112. doi: 10.1038/modpathol.2016.95 [17] Li Y, Liang L, Dai W, et al.Prognostic impact of programed cell death-1(PD-1) and PD-ligand 1(PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer[J].Mol Cancer, 2016, 15(1):55. doi: 10.1186/s12943-016-0539-x -
下载:
点击查看大图
图(1) / 表(5)
计量
- 文章访问数: 116
- HTML全文浏览量: 7
- PDF下载量: 6
- 被引次数: 0
